Investors sold shares of Illumina Inc. (NASDAQ:ILMN) on strength during trading on Thursday following insider selling activity. $63.96 million flowed into the stock on the tick-up and $89.51 million flowed out of the stock on the tick-down, for a money net flow of $25.55 million out of the stock. Of all companies tracked, Illumina had the 0th highest net out-flow for the day. Illumina traded up $0.99 for the day and closed at $137.17Specifically, SVP Charles Dadswell sold 8,632 shares of Illumina stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $155.00, for a total value of $1,337,960.00. Following the sale, the senior vice president now directly owns 40,248 shares in the company, valued at approximately $6,238,440. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Daniel Bradbury sold 600 shares of Illumina stock in a transaction on Friday, October 7th. The shares were sold at an average price of $184.36, for a total transaction of $110,616.00. Following the completion of the sale, the director now owns 17,065 shares in the company, valued at $3,146,103.40. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

A number of analysts have issued reports on ILMN shares. Vetr downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $167.08 price target on the stock. in a report on Monday, July 18th. CL King initiated coverage on shares of Illumina in a report on Tuesday, June 21st. They issued a “buy” rating and a $165.00 target price on the stock. Argus boosted their target price on shares of Illumina from $175.00 to $185.00 and gave the stock a “buy” rating in a report on Monday, August 8th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $190.00 target price on the stock in a report on Friday, August 26th. Finally, Citigroup Inc. boosted their target price on shares of Illumina from $175.00 to $190.00 and gave the stock a “buy” rating in a report on Monday, September 12th. Two equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Illumina currently has a consensus rating of “Hold” and an average target price of $156.88.

The firm has a market cap of $20.23 billion, a price-to-earnings ratio of 47.26 and a beta of 0.47. The company’s 50 day moving average is $171.14 and its 200-day moving average is $156.05.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.13. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The business earned $600 million during the quarter, compared to analyst estimates of $31.91 million. During the same quarter last year, the firm posted $0.80 earnings per share. The business’s revenue for the quarter was up 11.3% compared to the same quarter last year. On average, analysts predict that Illumina Inc. will post $3.53 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Baillie Gifford & Co. raised its position in Illumina by 3.8% in the second quarter. Baillie Gifford & Co. now owns 18,615,061 shares of the life sciences company’s stock valued at $2,613,182,000 after buying an additional 682,010 shares during the last quarter. Capital Research Global Investors raised its position in Illumina by 17.1% in the second quarter. Capital Research Global Investors now owns 13,085,071 shares of the life sciences company’s stock valued at $1,836,882,000 after buying an additional 1,910,346 shares during the last quarter. Vanguard Group Inc. raised its position in Illumina by 2.0% in the second quarter. Vanguard Group Inc. now owns 8,982,784 shares of the life sciences company’s stock valued at $1,261,004,000 after buying an additional 178,186 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its position in Illumina by 1.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 3,835,363 shares of the life sciences company’s stock valued at $538,408,000 after buying an additional 43,515 shares during the last quarter. Finally, Capital World Investors raised its position in Illumina by 218.0% in the second quarter. Capital World Investors now owns 1,463,000 shares of the life sciences company’s stock valued at $205,376,000 after buying an additional 1,003,000 shares during the last quarter. 95.22% of the stock is owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

5 Day Chart for NASDAQ:ILMN

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.